We previously reported, both in transfected cells and in human T-cell leukemia virus type-2 subtype B infected cells, that the viral transactivator Tax-2B protein could inhibit p53 functions. We have now investigated the mechanism through which Tax-2B represses p53 using GFPTax-2B fusion proteins. We present evidence that Tax-2B inhibition of p53 function is not linked to CREB/ ATF activation, but is uniquely correlated with the interaction of CREB binding protein (CBP), but not p300, with the C-terminus of Tax-2B. Wild type, but not a Tax-2B-M47 mutant, inhibits p53 function in adherent cells. We demonstrate that both Tax-2B and Tax-2B-M47 can bind p300, while Tax-2B-M47 is impaired for CBP binding. Importantly, transfection of increasing amounts of CBP but not p300 or p300/CBP-associated factor (P/CAF) could rescue p53 transcriptional activity in the presence of Tax-2B in nonlymphocytic cells. In lymphoid cells, Tax-2B mediated inhibition of p53 is correlated with the NF-jB pathway activation and could be prevented by the overexpression of an IjBa mutant. Given the similarities between the functional domains of CBP and p300, these results are intriguing and suggest that Tax-2B must bind the CR2 domain of CBP, but not that of p300 in order to repress p53.
Introduction
The human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are closely related human retroviruses that infect CD4 þ and CD8 þ T cells in vivo and in vitro (Ijichi et al., 1992; Wang et al., 2000; Johnson et al., 2001) . HTLV-1 is the etiological agent of the adult T-cell leukemia/lymphoma (ATL) and of the tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/ HAM) (Poiesz et al., 1980; Yoshida et al., 1982; Gessain et al., 1985) . By contrast, although initially isolated from a case of atypical hairy T-cell leukemia (Kalyanaraman et al., 1982) , HTLV-2 has not been formally associated with any T-cell malignancy (Fouchard et al., 1995) . It has rather been linked with some 'TSP-like' neurological disorders (Murphy et al., 1997) .
HTLV-1 and -2 genomes encode, respectively, the Tax-1 and -2 proteins, whose role is to transactivate the viral promoter. HTLV-1 and -2 Tax sequences display 26-28% divergence at the nucleotide level and at the amino-acid levels, respectively (Lewis et al., 2002) . So far, six subtypes of HTLV-1 (A-F) and four of HTLV-2 (A-D) have been described. Regardless of the subtype, Tax-1 proteins have very closely related sequences. In contrast, HTLV-2B, -2C and -2D Tax proteins, retain similar but not identical length (353 and 356 amino acids, respectively). Strikingly, HTLV-2A Tax is shorter (331 amino acids). Recent studies demonstrated that like Tax-1, Tax-2A and -2B proteins are able to activate both the CREB/ATF and the NF-kB signaling pathways Lewis et al., 2002) . However, although Tax-2 has the ability to immortalize T cells in vitro (Ross et al., 1996 (Ross et al., , 2000 , it was shown to transform rat fibroblasts less efficiently than Tax-1, and to lack micronuclei inductive ability (Semmes et al., 1996; Endo et al., 2002) .
Several reports have now established the critical role of Tax-1 in the immortalization and in the transformation of T cells (Grassmann et al., 1994; Iwanaga et al., 1999) . One transformation target of Tax-1 is the p53 tumor suppressor, which is of key importance in the protection of the cell against carcinogenesis. Using transient transfections, several investigators have now demonstrated the inhibition of p53 transcriptional activity by the HTLV-1 Tax protein (Uittenbogaard et al., 1995; Cereseto et al., 1996; Mulloy et al., 1998; Pise-Masison et al., 1998a; Suzuki et al., 1999; Ariumi et al., 2000; Van et al., 2001) . This might explain why high levels of inactive, wild-type p53 have been found in most HTLV-1 immortalized or transformed cells tested, as well as in freshly isolated cells obtained from ATL patients (Reid et al., 1993; Yamato et al., 1993; Gartenhaus and Wang, 1995; Cereseto et al., 1996; Akagi et al., 1997; Takemoto et al., 2000) .
Recent studies have presented seemingly conflicting thoughts as to how Tax-1 represses p53 functions. Pise-Masison et al. (1998a reported that, depending on the cell-type, Tax-1 uses different pathways (i.e. CREB/ATF or NF-kB) for inhibiting p53 functions. Franchini, Jeang and Shimotohno's laboratories have suggested that the activation of the CREB/ ATF signaling pathway by Tax-1 plays a critical role both in lymphoid and adherent cell lines (Mulloy et al., 1998; Ariumi et al., 2000; Van et al., 2001) . In the CREB/ATF inhibition pathway, Tax-1 markedly inhibits the p53 activity through the sequestration of either the CREB-binding protein (CBP) or of p300 (Suzuki et al., 1999; Van Orden et al., 1999; Ariumi et al., 2000; Pise-Masison et al., 2001 ; Van et al., 2001; Livengood et al., 2002) . Of note, in these studies, the Tax-1 mutants that were impaired for CBP/p300 binding were consequently impaired for CREB activation. Therefore, these studies did not elucidate whether only Tax-1 binding to CBP or to p300 is sufficient to inhibit p53 functions or whether activation of the CREB/ATF pathway by Tax-1 is also needed.
We have previously reported that Tax-2B could inhibit p53 transcriptional activity as efficiently as Tax-1. However, the mechanism of p53 repression by Tax-2B was not clear. Using GFP-Tax fusion protein that is impaired for CREB, but wild type for NF-kB activation, we have now investigated the mechanism through which Tax-2B represses p53 functions in different cell lines. We present evidence for major and novel differences between HTLV-1 and HTLV-2 Tax proteins. We show for the first time that in all cell lines tested, p53 inhibition by Tax-2B is not correlated to the CREB/ATF activation. In T cells, as it is the case for Tax-1, the inhibition of p53 by Tax-2B is associated with the activation of the NF-kB pathway. However, in nonlymphocytic cells, we demonstrate that while Tax-1 can use CBP or p300 for inhibiting p53 Tax-2B specifically utilizes CBP.
Results
A GFP-Tax-2 fusion protein that is wild type in sequence is deficient from the CREB/ATF pathway activation but retains its ability to activate the NF-kB pathway
We previously reported that tagging either the Nterminus or the C-terminus of Tax-2 abolishes its activity on the HTLV-1 LTR . Therefore, in order to discriminate between the requirement of activating CREB or NF-kB for repressing p53, we decided to use a GFP-tag-Tax2 (GFP-2B) construct. GFP and GFP-2B expression were first analysed in Jurkat lymphoid cells. FACS analysis allowed the detection of a GFP signal in Jurkat cells that were transfected with GFP-and GFP-2B-expressing vectors, but not in the control cells ( Figure 1a ). As Tax-2 has been shown to transactivate the heterologous promoter (i.e. the HTLV-1 LTR) (Shah et al., 1986; Semmes et al., 1996; Ross et al., 1997; Mahieux et al., 2000) as well the homologous promoter (i.e. HTLV-2 LTR), we then performed a series of transient transfection in different cell types to determine the transcriptional activity of the GFP-Tax protein using HTLV-LTR luciferase constructs (Figure 1b and c) . As controls, two Tax-1 mutants (M22 and M47) were used (Smith and Greene, 1990) . M22 (T 130 L 131 -A 130 S 131 ) displays nearly wildtype transactivation of the HTLV-1 LTR, but fails to significantly activate the NF-kB pathway. M22 mutations alter the third of four regularly spaced leucine residues in the linear sequence of Tax-1 (Smith and Greene, 1990) . This mutant has been reported to be partially defective for dimerization and has a reduced affinity for CREB (Smith and Greene, 1990; Tie et al., 1996) . On the contrary, M47 (Leu 319 Leu 320 -Arg 319-Ser 320 ) displays nearly wild-type activity on the NF-kB pathway, but has an impaired activity on the HTLV-1 LTR (Smith and Greene, 1990) . The cause of this defect has been reported to be the inability of M47 to bind P/ CAF (Jiang et al., 1999) . The Tax-2 M47 mutant (Ile 319 Leu 320 -Arg 319 Ser 320 ), which has a similar phenotype to that of Tax-1 M47 (Ross et al., 1997) , was also used. As expected, the GFP-2B protein was found to be impaired for CREB/ATF activation in Jurkat cells both on the HTLV-1 and on the HTLV-2 LTR (Figure 1b , lane 5, Figure 1c , lane 4). The GFP-2B activity was similar to that of the Tax-1 mutant M47 that is CREB defective (Figure 1b , see lane 3 vs 5). Since the Nterminus domain of Tax has been reported to be critical for CREB binding (Adya and Giam, 1995; Goren et al., 1995) , it is likely that the GFP fusion prevents Tax from binding CREB. Consistent with this hypothesis, removing the GFP fusion restored Tax-2B ability to activate transcription from the HTLV-2 LTR ( Figure 1c, lane 2) or from the HTLV-1 LTR (data not shown). In contrast, the co-transfection of the pGFP-2B plasmid together with a NF-kB luciferase reporter construct allowed us to show that the protein retains the ability to activate this pathway ( Figure 1d ). As controls, the Tax-1 M22 and M47 mutants displayed the expected phenotype ( Figure 1e ). Thus, this GFP-Tax-2 protein that is wild type in sequence has the same phenotype as the Tax-1 M47 (i.e. CREB À , NF-kB þ ) and can be therefore used to distinguish which pathway is needed for repressing p53.
P53 repression by Tax-2B is correlated with the activation of the NF-kB pathway in T cells
In Jurkat cells, Tax-1 represses p53 transcriptional activity via the activation of the NF-kB pathway (PiseMasison et al., 2000) . We therefore performed a series of experiments using the PG13 luc construct that contains 13 p53-responsive elements, in the presence of the different Tax-expressing vectors ( Figure 2a) . As previously described, Tax-1wt (pcTax) or Tax-1 mutant M47, but not Tax-1 mutant M22, were able to repress p53 activity. Similarly, the GFP-2B protein but not the GFP-expressing backbone vector repressed p53 functions ( Figure 2a Jurkat demonstrated that the downregulation of p53 transcriptional activity was not due to a p53 decreased expression in the cells (Figure 2b ).
Activation of the CREB/ATF pathway is not necessary for Tax-2B to repress p53 functions in HEK or in Hela cells
To investigate whether, as suggested for Tax-1, the mechanism of p53 repression by Tax-2B was CREB/ ATF dependent in non-T cells, we performed the same experiments in HEK cells. Strikingly, the GFP-2B but not the GFP backbone vector retained its ability to repress p53 transcriptional activity in HEK cells ( Figure 2c lane 6 vs 7). This suggests that the activation of the CREB/ATF is not necessary for Tax-2B for repressing p53 functions in these cells. A p53 Westernblot demonstrated that the down-regulation of p53 transcriptional activity in HEK cells was not due to a decreased expression of p53 in the cells (Figure 2d ). Of note, the detection of p53 in the control lane (i.e. without ectopically expressed p53) is linked to the fact that HEK cells are known contain detectable levels of inactive p53 (Yu et al., 2001) . As a control Tax expression was also assessed ( Figure 2d ). All Tax-1 proteins (i.e. WT, M22 and M47) were expressed at similar levels ( Figure 2d ). As previously reported (Alefantis et al., 2003) , GFP protein levels were higher as those of GFP-2B. Since p53 inhibition by Tax-1 has not been previously investigated in HEK cells, we repeated the experiments using Hela cells, which have been extensively used for this purpose. Previous reports suggested that expression of the M22 but not M47 Tax-1 mutants inhibited p53 transcriptional activity in Hela cells (Mulloy et al., 1998; Pise-Masison et al., 2001) . We therefore performed this The IkB S32/36A dominant-negative construct prevents Tax-2B from inhibiting p53 functions in T cells but not in adherent cells
To define whether the NF-kB activation is critical or not for the repression of p53, we used the dominant-negative IkB S32/36A mutant construct that prevents the . This confirmed that Tax-2B uses the activation of the NF-kB pathway for repressing p53 functions in T cells. The transfection of the IkB S32/36A in the absence of Tax had no effect on p53 activity in these cells (data not shown).
In both HEK (Figure 3b ) and in Hela (data not shown) adherent cells, the presence of the IkB S32/36A did not significantly prevent the repression of p53 by the different Tax proteins (Figure 3b , see lane 4 vs 5 and 6 vs 7). These results demonstrate that the activation of the NF-kB pathway by Tax-2B or by Tax-1 is not required for repressing p53 function in these cells. As in Jurkat (data not shown), the transfection of the IkB S32/36A in the absence of Tax had no effect on p53 activity (Figure 3b, lane 2 vs 3) . Moreover, Tax expression was similar in the presence or absence of IkB S32/36A (Figure 3c ). Finally, a control experiment demonstrated that, at the same concentrations, the IkB S32/36A mutant prevented the NF-kB activation in Hela cells as well as in HEK (Figure 3d and data not shown). 
GFP-2B-M47 is defective for p53 repression in HEK and Hela cells
Interestingly, our results demonstrated that neither the activation of CREB nor the activation of NF-kB seems necessary for Tax-2B-mediated p53 repression. However, as Tax-1 M47 does not repress p53 in Hela cells (see Figure 2e) , the ability of the GFP-2B-M47 mutant to repress p53 was tested (Figure 4a) . Although GFP-2B-M47 has the same NF-kB and CREB/ATF phenotype as the pGFP-2Bwt construct, that is, CREB/ATF -/ NF-kB þ (Figure 1c and data not shown) and a similar level of expression (Figure 4b) , it is impaired for inhibiting p53. Similar results were obtained with the pSG5M-2BM47 mutant (described in Figure 1c) , which lacks the GFP fusion protein (data not shown). These results suggest that the 2B-M47 mutant has another defect that makes it unable to repress p53 in nonlymphocytic cells.
The GFP-Tax wt but not GFP-2BM47 constructs bind to p300 and CBP in vitro Tax-1 binds at least two different domains of CBP/p300: the KIX domain and the CR2 domain. The regions spanning amino acids 81-95 and 312-319 of Tax-1 have been shown to be critical for the Tax-1-CBP/p300 interactions (Bex et al., 1998; Harrod et al., 1998; Scoggin et al., 2001) . Tax-1-M47L 319 L 320 -R 319 S 320 has been reported to be defective for CBP binding (Bex et al., 1998) . This defect is probably linked to a default in the CR2 binding due to the L-R change at position 319 (Scoggin et al., 2001) , since the 81-95 amino-acid sequence is identical to that of wild-type Tax-1. In order to define whether Tax-2 and Tax-2M47 bind or not to CBP and to p300, a series of p300 ( Figure 5c ) and CBP (Figure 5a) immunoprecipitations, followed by GFP Western blot, was performed with the GFP-2B constructs. A GFP-Tax-1 (GFP-1) construct was also made and used as a positive control for CBP/p300 binding, while the GFP backbone vector was used as a negative control. This allowed us to determine that Tax-2Bwt binds to p300 and CBP, but Tax-2B-M47 is impaired for CBP binding. 293T cells were transiently transfected with the different GFP constructs (0.5 mg). Extracts were prepared and 200 mg was incubated with purified His-tagged p300 or Histagged CBP from baculovirus. Immune complexes were captured using nickel beads. After resolution, proteins were electroblotted to nylon membranes. GFP-2Bwt binds both p300 and CBP (Figure 5a and c, lane 3). As a control, GFP-Tax-1 wt also binds p300 and CBP (Figure 5a and c, lane 2), while the GFP protein alone does not bind p300 or CBP in vitro (Figure 5a and c, lane 1). Of note, GFP-Tax-2B binds less efficiently CBP than GFP-Tax-1 does (Figure 5a , compare lanes 2 and 3), while both Tax proteins bind p300 equivalently (Figure 5c , compare lanes 2 and 3). This latter result suggests that, as compared to Tax-1, natural mutations in the Tax-2 sequence at position 85 and in the 312-319 domain have a selective impact on Tax-2/CBP interactions. As controls, CBP and p300 input levels were assessed and revealed that identical amounts of proteins have been used for the immunoprecipitations (Figure 5b  and d) . Strikingly, the GFP-2B-M47 mutant which possesses a wild-type KIX-binding sequence as compared to Tax-2B was impaired for CBP binding ( Figure 5a , lane 4). Nevertheless, GFP-2B-M47 retained its ability to bind p300 ( Figure 5c , lane 4). These results as well as the luciferase experiments therefore suggest that the Tax-2B amino-acid 319-320 sequence (i.e. near the CR2-binding sequence; Scoggin et al., 2001 ) is critical for the binding to CBP but not to p300. As a control, the GFP and GFP-Tax protein input were assessed (Figure 5e ).
Tax-2b selectively uses CBP but not p300 for inhibiting p53 functions
Since previous reports indicated that HTLV-1 Tax can squelch CBP and p300 indifferently in order to repress p53 in adherent cells, we investigated whether this was the case for Tax-2B. As the GFP-2B-M47 mutant that cannot repress p53 in adherent cells is also impaired for CBP and most probably for P/CAF binding but not for p300 binding, we conducted a series of rescue experiments with increasing amounts of PCAF, p300 or CBP. In a first series of experiments, ectopically expressed p300 synergized with p53 for activating transcription from the PG13 reporter construct (Figure 6a ). As a control, the levels of Flag-p300 and of p53 were assessed by Western blot (Figure 6b ). Similarly P/CAF increased Tax-1 activation of the LTR (Figure 7a ). This demonstrated that, after their transfection into cells, p300 and P/CAF were expressed and active. A series of experiments was then performed with increasing amounts of either p300 (Figures 6c and d) , PCAF (Figure 7b ) or CBP ( Figure 7c ) in order to rescue p53 activity in the presence of pGFP-2B or pcTax. Even with high doses (i.e. pGFP-2B/p300 or P/CAF ratio ¼ 1/10) of coactivators, we did not observe a significant recovery of p53 transactivation in the presence of GFP-2B (see Figure 6c , lane 6 vs 2, and Figure 7b , lane 6 vs 2). Similar results were obtained in Hela cells (data not shown). In contrast, when HTLV-1 Tax was present in a control experiment, we could rescue p53 activity in the presence of increasing amount of p300 (Figure 6d , lane 6 vs 3). This implies that a direct squelching of the p300 or PCAF co-activators by Tax-2B is unlikely to be the cause of p53 inactivation in these cells. Of note, increasing the amount of transfected p300 co-activator had an impact on the steady-state levels of Tax-2 and Tax-1 (see Figure 6e and f). However, the fact that Tax-2 levels increase in the presence of high doses of p300 (Figure 6e ) was not the cause of the constant repression of p53 activity, since Tax-1 protein levels also increased when p300 was cotransfected, while p53 activity was restored (Figure 6f) . A moderate effect on the steady state of p53 was also noted (see Figures 6c and d , lanes 5, 6 vs 2). As suggested by our co-activator immunoprecipitation results, p53 activity was uniquely recovered in the presence of increasing amounts of CBP in HEK (Figure 7c ) as well as in Hela cells (data not shown). As with the p300 experiment, the steady-state level of GFP-2B was also increased in the presence of a high amount of CBP. This confirms that transfecting these co-activators has a general effect on Tax level that is not linked to p53 transcriptional activity. Altogether, our results suggest that, in order to inhibit p53 functions, Tax-2B must specifically bind CBP. p53 control Western blots were also performed (Figures 7b and c) . Of note, P/CAF transfection had no effect on the steady state of Tax, nor of p53.
Discussion
The loss of p53 function, as a consequence of mutations or inactivation, increases the chances of genetic damage. Indeed, the importance of p53 as a tumor suppressor is evident from the fact that over 60% of all human cancers have a mutant or inactive p53 (Nigro et al., 1989) . As HTLV-1 infection can lead to leukemia, p53 status has been extensively studied in HTLV-1-infected cell lines. Mutations of the p53 tumor-suppressor gene were detected in 20-30% of all ATL patients (Sugito et al., 1991) , mostly in advanced cases, suggesting the involvement of p53 mutation in a late stage of leukemogenesis, or as a consequence of the cancerous transformation (Nagai et al., 1991) .
Several laboratories have shown that wild-type transcriptionally inactive p53 was present in most HTLV-1-infected cells and that Tax-1 protein alone could inhibit p53 functions. In T cells, different models have been proposed: (1) Tax-1 represses p53 functions through the activation of the NF-kB pathway (PiseMasison et al., 2000) ; (2) Tax-1 needs to activate the CREB/ATF pathway in order to repress p53 (Mulloy et al., 1998) . In nonlymphoid cells, Tax-1 represses p53 through the direct squelching of either the CBP or the p300 co-activators (Mulloy et al., 1998; Van Orden et al., 1999; Ariumi et al., 2000; Livengood et al., 2002) . The ATM pathway might also be involved (Van et al., 2001) .
We and others have previously shown that HTLV-2 subtype A Tax protein was impaired for repressing p53 in lymphocytes or in Hela and Saos-2 cells, while Tax-1 and Tax-2B were equivalent for inhibiting p53 function in all cell types tested Van et al., 2001) . In this report, we have investigated the mechanism through which Tax-2B represses p53 in different cell lines (i.e. lymphoid and nonlymphoid). Consistent with previous results obtained for Tax-1 (Pise-Masison et al.,
2001
), we show that in T cells Tax-2B-mediated repression of p53 is correlated with the activation of the NF-kB pathway.
Remarkably however, in non-T cells, Tax-2B effects are not linked to the activation of the CREB/ATF or NF-kB pathways. Our rescue experiments suggest that Tax-2B does not use p300 or PCAF, but uniquely uses CBP binding to inhibit p53 functions. The binding experiments also suggest that CBP has a lower affinity for Tax-2B than p300. This would explain why Tax-2B-M47 still binds p300 while the same mutant fails to bind CBP even if its KIX-binding sequence is wild type. This could be linked to the fact that the CR2 domains of CBP and p300 are relatively divergent (B50%) (Scoggin et al., 2001) . The CBP/CR2-binding sequence of Tax-2 therefore appears to be needed for repressing p53. Altogether, our results demonstrate that, although CBP and p300 are often referred to as CBP/p300, these two coactivators are not functionally redundant and therefore do not have the same role in p53 functions in the presence of Tax-2B. Strikingly, this is not the case with Tax-1, where either CBP or p300 overexpression can restore p53 functions. Of note, distinct roles of the coactivators p300 and CBP have also been reported in retinoic-acid-induced F9-cell differentiation (Kawasaki et al., 1998) . As p300 and CBP possess histone acetyltransferase (HAT) activity, it would also be of interest to determine whether post-translational modifications such as deacetylation occur concomitantly to p53 loss of activity in the presence of Tax-2B in nonlymphocytic cells (Pearson et al., 2000) . Indeed, it was recently shown that p53 was hypo-acetylated at residues K320 in the presence of the HIV-1 Tat protein, which represses its transcriptional activity (Harrod et al., 2003) . This is due to a competition between Tat and p53 for the binding to PCAF. However, our preliminary results show that even in the presence of p53 mutants (K320-R and K382-R) p53 function is still inhibited by Tax-2B in nonlymphocyte cells (Meertens and Mahieux, unpublished data) .
Interestingly, both Tax-1 and Tax-2B repress p53 in vitro, but, in contrast to HTLV-1 whose etiological role in ATL is now well established, there is currently neither a serological association nor molecular evidences that would definitively associate HTLV-2 with a malignant lymphoproliferation disease. This may suggest that the Tax-2B-mediated repression of p53 per se is necessary but not sufficient for inducing malignancy in vivo, and that other cellular partners different from p53 may be required for promoting Tax ability to transform. Indeed, two recent reports have suggested that the selective interaction of Tax-1 but not Tax-2B with proteins that contain a PDZ domain was critically involved in the transforming activity of Tax1 (Endo et al., 2002; Hirata et al., 2004) . It is therefore possible that a combination of p53 inactivation and PDZ binding is required for a fully efficient leukemogenesis.
HTLV-2 has, nevertheless, been involved in some rare cases of T CD8 þ lymphoproliferative disorders. Since ATL occurs in a very limited number of HTLV-1 carriers, the association between ATL and HTLV-1 infection was uncovered because of the large number of infected individuals living in Japan. There is not really Selective use of co-activator by HTLV-2B Tax L Meertens et al such a population infected with HTLV-2B, perhaps giving the false impression that HTLV-2B viruses are nonpathogenic.
In conclusion, we present evidence for important and major differences between HTLV-1 and HTLV-2 Tax proteins. In nonlymphocytic cells, Tax-2B utilizes a unique mechanism that does not involve the activation of the CREB/ATF or NF-kB pathways nor a direct p300 binding, but is linked to CBP. This is, to our knowledge, the first example of a selective use of these co-activators by the Tax-2 protein. Given the percentage of similarity between the functional domains of Tax-2 and Tax-1 on one side, and the high homologies of functions between CBP and p300 on the other, our results are intriguing and suggest that sequence cannot predict function. This may also suggest that the unique ability of Tax-1 to utilize p300 for repressing p53 might contribute, in vivo, to the HTLV-1 induced adult T cell leukemia.
Materials and methods

Cell lines
Jurkat, Hela, HEK and 293T cell lines were used. The cells were grown in RPMI 1640 or in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% L-Gln and 1% penicillin/streptomycin at 371C in 5% CO 2 .
Flow cytometry
Jurkat cells were transiently transfected with the GFP or the GFP-2B vectors. After 36 h, cells were processed as previously described (Sol-Foulon et al., 2002) .
Immunoblot analyses
Cells were washed in phosphate-buffered saline and lysed (Tris-HCl 50 mM (pH 7.4), 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na 3 VO 4 , 1mM DTT) in the presence of protease inhibitors (Boehringer) for 20 0 on ice. The lysate was centrifuged for 10 0 at 41C and the supernatant frozen at À801C. Protein concentration was determined by Bradford. Tris-Glycine-gels, 4, 12 and 4-20% (InvitrogenNovex), were used as recommended by the manufacturer. After transfer to an Immobilon PVDF membrane (Biorad), Western blots were performed as previously described , using either the SuperSignal Westpico or the SuperSignal Westfemto chemiluminescent kits (Pierce). When needed, the membranes were stripped using the reWestern-blot recycling kit (Chemicon) and re-probed.
Antibodies
GFP antibody (R970-01) was purchased from Invitrogen (Invitrogen) or from Clontech, b-tubulin (sc-9104) from Santa Cruz, Histidin and Flag M2 from Sigma, HA (MMS-101R) from Covance and p53 (OP-43) from Calbiochem. The Tax-1 mAb Tab172 has been described elsewhere (Pise-Masison et al., 1998a) .
Tax constructions
The Tax sequences were amplified from Tax-1 (pcTax) and Tax-2B (pCG-Tax2B6) (Eiraku et al., 1996) containing plasmids and inserted downstream the GFP sequence into the MCS of a pGFP-C3 vector (Clontech, Palo Alto, CA, USA) after Sac1/EcoR1 digestion. Each of the resulting GFPTax construct was sequenced (Genome Express). The GFP-2B-M47 mutant was constructed by replacing the I 319 -L 320 amino-acid residues by R 319 -S 320 , using the Quickchange sitedirected mutagenesis (Stratagene) with the following primers: TAX-2M47s 5 0 CAA CAT CCC TGT CTC TAG GTC ATT TAA TAA AGG AGA GGC3 0 and Tax-2 M47 as 5 0 GCC TCT CCT TTA TTA AAT GAC CTA GAG ACA GGG ATG TTG3
0 . The Tax-2B and the Tax-2B M47 sequences were also inserted into the MCS of the pSG5M vector (generous gift of Dr C Pique).
Luciferase assays
Transient transfection experiments were performed with 3 Â 10 6 Jurkat cells or Hela, HEK and Cos-7 at 40-60% confluence. Jurkat cells were transfected using the Superfect procedure (Qiagen) as previously described . HEK and Hela cells were transfected using the Polyfect and Effectene reagents, respectively (Qiagen). The amount of DNA transfected was equalized by addition of a pcDNA3.1 empty vector. All the transfections were carried out in the presence of either pRSV-RL or pTK-RL vectors (Promega) in order to normalize the results for the transfection efficiencies. Reporter activities were assayed 18-24 h post-transfection using the Dual-Luciferase reporter assay system (Promega). Luciferase assays were performed with a Berthold LB9500C luminometer as described elsewhere . The PG13-luc, HTLV1-luc, HTLV-2-luc, NF-kB-luc, p53wt, pcTax and Tax-1 mutants M22, M47, pCMV4-HA-IkB(S32/36A) p300, CBP, PCAF have been described elsewhere (Jiang et al., 1999; Mahieux et al., 2000; Pearson et al., 2000; Pise-Masison et al., 2000; Casoli et al., 2004) .
Immunoprecipitation
293T cells were transfected using Fugene 6 reagent as described above with pGFP (0.5 mg), pGFP-1 (0.5 mg), pGFP-2B (0.5 mg), or pGFP-2B-M47 (0.5 mg). At 24 h after transfection, cells were washed twice with cold PBS and lysed in the presence of protease inhibitors for 20 0 on ice as previously described (Pise-Masison et al., 1998b) . Whole-cell extracts (200 mg) were incubated with 100 ng of columnpurified his-tagged p300 or his-tagged CBP overnight at 41C as previously described (Lu et al., 2002) . Nickel beads (Qiagen) were then added and reactions incubated for an additional hour at 41C. After extensive washing with lysis buffer, the complexes were run on 4-20% Tris-Glycine gels (Invitrogen/ Novex) and electro-blotted to nylon membrane (Immobilon-P). Western blot analysis was performed to detect GFP-fusion proteins using anti-GFP antiserum (Clontech).
